Papillary thyroid carcinoma susceptibility candidate 2 (non-coding) (PTCSC2)

Papillary thyroid carcinoma susceptibility candidate 2 (PTCSC2) is a long non-coding RNA gene located at chromosome 9q22, discovered due to its strong genetic association with the risk of papillary thyroid carcinoma (PTC) through the risk allele [A] of SNP rs965513[3][5]. PTCSC2 is characterized by multiple spliced isoforms, with primary expression in thyroid tissue and minimal or absent protein-coding potential[3]. It is transcribed in the opposite direction to the neighboring FOXE1 gene and shares a bidirectional promoter with FOXE1[2][5]. PTCSC2 acts as a regulatory lincRNA: it binds the protein MYH9, influencing the bidirectional FOXE1/PTCSC2 promoter, and interacts with FOXE1 to modulate downstream pathways including the p53 pathway critical for cell cycle regulation and tumorigenesis[2][5]. In normal thyroid, PTCSC2 expression is relatively high, but it is markedly downregulated or absent in PTC tumors and certain cancer cell lines, suggesting a tumor suppressor function. Forced PTCSC2 expression affects the expression of multiple coding and non-coding genes, especially those involved in the cell cycle and cancer-related networks[3][5]. Decreased PTCSC2 expression in the thyroid may serve as a biomarker for PTC risk, but there are no direct therapeutic drugs or mechanisms of action currently established for PTCSC2, as it is not a canonical drug target such as a receptor, enzyme, or transporter[2][3][5].

Other names

PTCSC2papillary thyroid cancer susceptibility candidate 2papillary thyroid carcinoma susceptibility candidate 2 (non-coding)lincRNA PTCSC2